<qa>  What is the name of the study that will use a 3-session within-subjectsDesign: The study will use a 3-session within-subjects double-blind design in which participants will receive single doses of buprenorphine 0, 0.2, 0.4 mg sublingual in randomized order. All screening, orientation, and study session procedures will take place in the Human Behavioral Pharmacology Laboratory suite in the L4 wing of 5841 S. Maryland Ave. 